Mylan stock bounces back from early losses after CEO blames FDA for drug delays

CEO Heather Bresch clarified on a call with investors that delaying Advair's launch to 2018 was due to the Food and Drug Administration reorganizing.
Source: CNBC

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>